Inhibikase Therapeutics
IKT
17 hedge funds and large institutions have $2.91M invested in Inhibikase Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
304% more capital invested
Capital invested by funds: $719K → $2.91M (+$2.19M)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
1.68% more ownership
Funds ownership: 0.95% → 2.63% (+1.7%)
11% less funds holding
Funds holding: 19 → 17 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.06M |
| 2 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$57.6K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$32.7K |
| 4 |
Renaissance Technologies
New York
|
+$10.6K |
| 5 |
VF
Virtu Financial
New York
|
+$9.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.3K |
| 2 |
Koshinski Asset Management
Decatur,
Illinois
|
-$5.35K |
| 3 |
SI
Sprott Inc
Toronto,
Ontario, Canada
|
-$5K |
| 4 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
-$217 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$65 |
IKT Hedge Fund Activity: Q1 2023 in Review
17 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2023, worth a combined $2.91M — up 304% from $719K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IKT and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.06M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $15.3K sold.
- 17 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2023, down from 19 in Q4 2022.
- Funds reported $2.91M of Inhibikase Therapeutics stock for Q1 2023, up 304% quarter-over-quarter.
- 3 funds opened new Inhibikase Therapeutics positions in Q1 2023 and 4 closed out, a net change of -1 holder.
- The largest Inhibikase Therapeutics buyer in Q1 2023 was Armistice Capital, an estimated $2.06M added.
- The largest Inhibikase Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $15.3K sold.
Based on aggregated 13F filings for Q1 2023.